Premium
SSRIs vs. SNRIs for anxiety and OCD
Author(s) -
Knopf Alison
Publication year - 2020
Publication title -
the brown university child and adolescent behavior letter
Language(s) - English
Resource type - Journals
eISSN - 1556-7575
pISSN - 1058-1073
DOI - 10.1002/cbl.30448
Subject(s) - discontinuation , anxiety , psychology , psychiatry , adverse effect , clinical psychology , medicine
Selective serotonin reuptake inhibitors (SSRIs) have greater adverse event (AE)–related discontinuation of treatment than serotonin‐norepinephrine reuptake inhibitors (SNRIs) in the treatment of pediatric obsessive‐compulsive disorder (OCD) and anxiety disorders. And SSRIs are more likely than SNRIs to produce “activation” (restlessness). They're better than SNRIs for anxiety, but for youths who are activated by SSRIs, clinicians should consider SNRIs, which have a lower risk of activation, researchers have found in a meta‐analysis published in the Journal of the American Academy of Child and Adolescent Psychiatry .